- Home
- DGICA vs KROS Comparison
DGICA vs KROS Comparison
Compare DGICA & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGICA
- KROS
- Stock Information
- Founded
- DGICA 1986
- KROS 2015
- Country
- DGICA United States
- KROS United States
- Employees
- DGICA N/A
- KROS N/A
- Industry
- DGICA Property-Casualty Insurers
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- DGICA Finance
- KROS Health Care
- Exchange
- DGICA Nasdaq
- KROS Nasdaq
- Market Cap
- DGICA 683.3M
- KROS 565.0M
- IPO Year
- DGICA N/A
- KROS 2020
- Fundamental
- Price
- DGICA $17.59
- KROS $15.56
- Analyst Decision
- DGICA Hold
- KROS Buy
- Analyst Count
- DGICA 1
- KROS 14
- Target Price
- DGICA $18.00
- KROS $20.56
- AVG Volume (30 Days)
- DGICA 163.2K
- KROS 474.1K
- Earning Date
- DGICA 10-23-2025
- KROS 08-06-2025
- Dividend Yield
- DGICA 4.17%
- KROS N/A
- EPS Growth
- DGICA 965.80
- KROS N/A
- EPS
- DGICA 2.34
- KROS 0.47
- Revenue
- DGICA $993,644,532.00
- KROS $232,844,000.00
- Revenue This Year
- DGICA $2.26
- KROS $5,579.44
- Revenue Next Year
- DGICA $2.96
- KROS N/A
- P/E Ratio
- DGICA $7.51
- KROS $33.43
- Revenue Growth
- DGICA 3.36
- KROS 85820.30
- 52 Week Low
- DGICA $14.06
- KROS $9.12
- 52 Week High
- DGICA $21.12
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- DGICA 49.23
- KROS 66.70
- Support Level
- DGICA $17.05
- KROS $14.04
- Resistance Level
- DGICA $17.70
- KROS $15.39
- Average True Range (ATR)
- DGICA 0.36
- KROS 0.60
- MACD
- DGICA 0.11
- KROS 0.13
- Stochastic Oscillator
- DGICA 84.68
- KROS 90.68
About DGICA Donegal Group Inc.
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.